Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : URMD -- Huge market potential -- Ignore unavailable to you. Want to Upgrade?

To: Milk who wrote (298)	7/27/1998 9:06:00 AM
From: TheCat	Read Replies (2) \| Respond to of 369

More good news to come shortly. It seems that Uromed did not include any marketing deal for Impress with the deal for Introl. This means that they may be selling entire Impress product. Impress is worth $50 million ($10 per share). Then URMD would be left with $100 million in cash and 3 major products (CaverMap, Breast Check and Radioactive Seeds). Stock split and de-listing questions overhanging the stock, but fundamentals of company have never been better. With stock price low, management is more motivated than ever to make deals.